News Feed

MPN News

MPN rss feedThe MPN News feed provides frequent updates on the latest happenings in the MPN World. Fresh content, with brief summary is automatically updated frequently from reliable sources.  Just click on the red hyperlink to pull up the complete news item.

Make PV Reporter your “starting point” for all MPN related news.

 

ASH Highlights Many patients wondered what happened to Fedratinib, the drug Sanofi had in trials several years ago. Amid some controversy, the drug was shelved, although many patients were experience positive responses. Fedratinib is back. It is a selective JAK2 Inhibitor, whereas existing treatments target both JAK1 & 2. Spleen [...]
Fri, Dec 15, 2017, Continue reading at the source
Marina Sampanes Peed Many of us in the MPN world have experienced: read a page and can't recall what you just read forget events, tasks, or activities that you used to remember difficulty in thinking clearly We jokingly call it “chemo brain” and chalk it up to various medications. But what if it's caused by [...]
Fri, Dec 15, 2017, Continue reading at the source
At the 59th American Society of Hematology (ASH) Meeting and Exposition, Rare Disease Report caught up with Ruben Mesa, M.D., Director of the University of Texas Health Cancer Center. In this video, he discusses the common problem of anemia that can come with myeloproliferative neoplasm (MPN)-associated myelofibrosis, how some of the [...]
Thu, Dec 14, 2017, Continue reading at the source
Data presented at the 2017 American Society of Hematology Annual Meeting (ASH 2017) are confirming previous studies suggesting that patients with polycythemia vera (PV) who fail hydroxyurea and are treated with ruxolitinib may have better hematocrit control. Researchers reported that patients treated with ruxolitinib appear to experience benefits in terms [...]
Thu, Dec 14, 2017, Continue reading at the source
Many clinicians suboptimally manage patients with polycythemia vera (PV) and myelofibrosis (MF), according to an analysis of data captured from an online tool developed by Clinical Care Options (CCO) in collaboration with a panel of PV and MF experts. The analysis was presented by Ryan Topping, PhD, at the 59th [...]
Thu, Dec 14, 2017, Continue reading at the source
MPN clinical interests
One Simple Criteria If your doc has never been to the ASH (American Society of Hematology) conference, the largest hematology convention in the world and never published a peer reviewed research paper, he/she ain't likely to be an MPN specialist. Also, if their bio lists 10 – 12 clinical interests, [...]
Fri, Dec 01, 2017, Continue reading at the source
Pegasys Jakafi combo for MPNs
This abstract is provided by Mads Emil Bjorn & Hans Carl Hasselbalch – Department of Hematology, Region Zealand, Roskilde, Denmark Abstract Introduction: The therapeutic landscape of the Philadelphia-negative myeloproliferative neoplasms (MPNs) is markedly changing consequent to the development of JAK-inhibitors and the use of ruxolitinib (RUX) in patients with myelofibrosis (MF) and patients [...]
Thu, Jun 29, 2017, Continue reading at the source
UT (University of Texas) San Antonio makes Dr. Ruben Mesa head of their Cancer Center Dr Ruben Mesa, one of the leading MPN Specialist in the world is accepting the role of the head of UT at San Antonio Cancer Center, where he will remain focused on MPN's. “Dr. Mesa's [...]
Thu, Jun 15, 2017, Continue reading at the source
Immunofluorescence of single human cell stained grown in tissue culture, stained with multiple antibodies and visualized via confocal microscopy
Abstract Myeloproliferative neoplasm cells recruit Gli1 positive mesenchymal stromal cells to transdifferentiate into fibrosis-causing myofibroblasts, a process that can be inhibited by a Gli inhibitor. Bone marrow fibrosis (BMF), characterized by deposition of reticulin and collagen fibers in the marrow, is a hallmark of primary myelofibrosis (PMF) and other myeloproliferative neoplasms (MPNs). [...]
Mon, Jun 05, 2017, Continue reading at the source
Understanding Polycythemia Vera (PV), A Rare Blood Cancer Behind the Mystery, Polycythemia Vera Every year, millions of patients, families and caregivers are impacted by cancer in the United States. Some cancers are well-known, but others are quite rare. Polycythemia Vera (PV) is part of a group of rare blood cancers called [...]
Fri, Apr 28, 2017, Continue reading at the source
For anyone who lives a fast-paced life, it is easy to sometimes forget our need to take care of ourselves and to listen to our bodies. It is easy to get distracted from the importance of a healthy lifestyle when it seems there is so much to be done. But it [...]
Tue, Mar 15, 2016, Continue reading at the source
February 29th is Rare Disease Day: 4 Reasons You Should Care Even though MPN patients who have a rare disease many may have never heard of "Rare Disease Day" and know next to nothing about the impact rare disorders have on society. Rare diseases play a larger role in public [...]
Mon, Feb 29, 2016, Continue reading at the source
It's World Cancer Day There has been, from time to time, a question about whether myeloproliferative neoplasms are cancers. Let's be clear, they are. But don't take our word for it. Cancer Support Community defines Myeloproliferative Neoplasms (MPNs) as types of blood cancers that overproduce blood cells in the bone [...]
Mon, Feb 01, 2016, Continue reading at the source
For the past several months we've kept you informed and taking action on Medicare's pending decision of whether to provide coverage for people with myelofibrosis seeking a stem cell transplant. Currently there is no official ruling from Medicare on whether this treatment is covered, leaving many patients to risk paying [...]
Tue, Jan 12, 2016, Continue reading at the source
Each year for the past three years, Cure Magazine and Incyte Corporation have recognized efforts within the MPN community with their MPN Hero award. The two categories are commitment to the community or individual. Past winners have included Ruben Mesa, Zhenya Senyak, Joyce Niblack, Richard Silver, and many more. We [...]
Sun, Dec 27, 2015, Continue reading at the source
According to a paper published in Nature Medicine, the drug MLN8237 (or Alisertib) has reduced tumor cells, blood counts and fibrosis in mouse models of myelofibrosis. Reports John Crispino, PhD, "This new paper shows that Alisertib has an anti-tumor effect in samples of myelofibrosis, similar to what we saw in [...]
Tue, Dec 01, 2015, Continue reading at the source


Check out more resources at MPN Cancer Connection!Click here
error: Content is protected !!